E-Selectin and markers of HIV disease severity, inflammation and coagulation in HIV-infected treatment-naïve individuals by Hoffman, Madelein et al.
E-Selectin and markers of  HIV disease severity, inflammation and coagulation 
in HIV-infected treatment-naïve individuals 
Madelein Hoffman1, Hayley Ipp2, Dineo V Phatlhane1, Rajiv T Erasmus1, Annalise E Zemlin1
1. Division of  Chemical Pathology, National Health Laboratory Service (NHLS) and Stellenbosch University, 
    Tygerberg Hospital, Cape Town, South Africa.
2. Division of  Haematology, National Health Laboratory Service (NHLS) and Stellenbosch University, 
    Tygerberg Hospital, Cape Town, South Africa.
Emails:
Madelein Hoffman: madeleinhoff@gmail.com, Hayley Ipp: drkaplan@telkomsa.net, Dineo V Phatlhane: dineo.phat-
lhane@nhls.ac.za, Rajiv T Erasmus: rte@sun.ac.za, Annalise E Zemlin: azemlin@sun.ac.za 
Abstract:
Background: E-selectin has been shown to play a role in atherosclerosis and to be increased in HIV-infected individuals due to 
chronic immune activation. There is a paucity of  studies on E-selectin in HIV-infected treatment-naïve individuals. 
Objectives: This study aimed to determine whether E-selectin levels were increased in HIV-infected treatment-naïve individuals 
and whether these correlated with markers of  disease severity, inflammation and coagulation to determine if  this population is 
at risk for cardiovascular disease (CVD).
Methods: E-selectin levels were determined in 114 HIV-infected treatment-naive and 66 HIV-negative individuals, compared 
between groups and correlated with markers of  disease severity, inflammation and coagulation.
Results: There were statistically significant differences (p<0.01) in levels of  WCC, CD4+ count, %CD38/8, albumin, IgG, 
hsCRP and D-dimer between groups and no statistically significant differences in E-selectin (p=0.84) and fibrinogen (p=0.65) 
levels. E-selectin correlated with age (p=0.02) and gender (p=0.01). 
Conclusion: E-selectin was a poor marker in this setting. There was no correlation with any of  the markers of  disease severity, 
inflammation and coagulation. E-selectin is most likely raised in an acute inflammatory setting, rather than chronic stage of  
HIV-infection. We recommend that other markers be utilized to identify patients at increased risk of  CVD; as these were signifi-
cantly increased untreated in individuals.
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More than 30 years of  intensive research has resulted in 
infection with Human Immunodeficiency virus (HIV) 
changing from a death sentence to a manageable disease.1 
HIV infection is characterised by ongoing immune acti-
vation and exhaustion of  the T-cell pool which results in 
immunosenescence and progression to Acquired Immu-
nodeficiency Syndrome (AIDS).2 Chronic immune activa-
tion leads to the accelerated development of  age-related 
disorders such as atherosclerosis and cardiovascular dis-
ease (CVD).3-6 Atherosclerosis is a chronic process involv-
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ing atherosclerotic plaque formation in the arterial wall.4 
Endothelial cell dysfunction is regarded as an early step in 
atherosclerotic plaque formation, where the defective en-
dothelium interacts with pro-inflammatory stimuli such as 
oxidised low density lipoprotein and results in endothelial 
activation with expression of  adhesion molecules.4 The 
persistent immune activation associated with HIV-infec-
tion has been associated with an increased risk of  CVD 
and this persists even after initiation of  treatment.3,7 HIV 
elite controllers who maintain viral suppression without 
treatment, have increased immune activation and associ-
ated CVD.8 The drivers of  this immune activation and 
subsequent atherosclerosis are thought to be mainly due 
to HIV-specific proteins, co-infections and gut transloca-
tion.9 HIV-specific proteins may activate plaque macro-
phages and promote platelet adhesion, thereby accelerat-
ing disease and plaque rupture. An increased prevalence 
of  plaques has been found in asymptomatic HIV-infec-
tion and in fact CVD is currently the third leading cause 
of  death in HIV-infection.10 
 
E-selectin is an adhesion molecule found on the surface 
of  activated endothelial cells during periods of  stress or 
inflammation.3,11,12  E-selectin is expressed in response to 
pro-inflammatory cytokines such as tumour necrosis fac-
tor (TNF)-a and interleukin (IL)-1.13,14 It recruits leuko-
cytes to the endothelium by binding ligands on their cell 
surfaces and facilitating their rolling on endothelial cells. 
This slows down the leukocytes and facilitates their even-
tual entry into the sub-endothelial space.11,12 
 
Inflammation caused by HIV infection activates lym-
phoid B-cells to produce antibodies. The antibodies IgM 
and IgG are able to control viral replication, but not re-
duce it.15 This causes continuous immune activation with 
ultimate B-cell dysfunction and polyclonal hypergamma-
globulinaemia.16 Studies have shown that increased IgG 
levels are associated with aggravated atherosclerosis and 
HIV disease progression.17,18
 
HIV disease severity is determined by the viral load and 
the CD4+ count.2 CD38 is a glycoprotein found on the 
surface of  immune cells such as CD4+ and CD8+-T lym-
phocytes, and is considered a marker of  immune cell acti-
vation.2 Studies have found that higher levels of  activated 
T-cells expressed by levels of  CD38 on CD8+T-cells pre-
dict an adverse prognosis19 and disease progression, re-
gardless of  the CD4+ count in HIV infection.20 Further-
more, the expression of  CD38 correlates strongly with 
the viral load, suggesting that CD38/8 could be used as a 
marker of  viral replication.20 
 
Studies have shown that non-specific markers of  inflam-
mation such as albumin and high sensitivity C-reactive 
protein (hsCRP) are altered in HIV infection.21 Serum 
albumin is a negative acute phase reactant and has been 
found to be a strong predictor of  mortality22 and pro-
gression to AIDS.22,23 Increased catabolism of  albumin 
due to inflammation, worsening of  nutritional status and 
degradation in the liver due to chronic infection have 
been reported as causes for reduced levels.21,23,24  HsCRP, 
an acute phase reactant protein produced by the liver in 
response to IL-6 indicates low grade inflammation and is 
thus useful in the assessment of  cardiovascular risk.25
 
A hypercoagulable state also seems to exist in HIV infec-
tion.6,26 Fibrinogen, an acute phase reactant, interacts with 
platelets resulting in their activation and fibrin formation. 
An increased fibrinogen level is associated with a 7-fold 
increase in all-cause mortality.27 The degradation of  fibrin 
generates soluble fibrin fragments such as D-dimer. Ele-
vated levels of  D-dimer are seen in all haematological dis-
orders that cause activation of  coagulation such as acute 
venous thromboembolism and CVD.28 Elevated D-dimer 
levels have been shown to be a strong independent pre-
dictor of  mortality and cardiovascular risk in HIV infec-
tion.28-30
 
Previous studies examining levels of  E-selectin in HIV 
infection have been controversial.31-37 The aim of  this 
study was to determine whether E-selectin levels would 
be increased in a young HIV-infected treatment-naïve 
study population and whether these would correlate with 
markers of  disease severity, inflammation and coagula-
tion to determine if  this study population is at increased 
risk for CVD.
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Methods
Study setting and population
This was a cross-sectional study of  114 HIV-infected 
antiretroviral therapy (ART)-naïve and 66 HIV-negative 
individuals. All participants were recruited from an HIV 
counselling and testing (HCT) clinic in Emavundleni 
Crossroads, Cape Town. This clinic forms part of  the 
Institute for Infectious Disease, Desmond Tutu HIV 
centre, University of  Cape Town (UCT) and employs the 
national HCT algorithm with accredited rapid HIV tests.
 
Clinical information was recorded on a standard form by 
the investigator during the interview. Data collected in-
cluded: (i) demographic details: age, gender and ethnic 
group; (ii) medical history: HIV status, date of  HIV diag-
nosis and most recent CD4+ count if  available; (iii) medi-
cation use including vitamins and herbal preparations.
 
All participants older than 21 years of  age, clinically 
healthy/asymptomatic, and ART-naïve were included. 
Participants with concurrent infections, tuberculosis 
(TB), on anti-TB or other antibiotic therapy and who 
were pregnant were excluded from the study. 
 
Laboratory measurements
Participants were initially screened for HIV using the 
HIV-1/2 Ag/Ab combo by AlereTM. The confirmatory 
test was the Uni-goldTM Recombigen® HIV.
 
E-selectin was determined in duplicate on serum samples 
stored at -70°C using the E-selectin human ELISA kit 
(abcam®, Cambridge, UK). According to the manufac-
turer’s specifications, samples are stable when stored at 
this temperature. The limit of  detection is < 0.5 ng/mL 
and the average E-selectin concentration for this assay as 
determined by the manufacturers on 80 normal subjects 
was found to be 51.99 ± 26.65 ng/mL (range 11.78 – 
160.72 ng/mL).  A lyophilised internal quality control of  
known concentration was used to determine the coeffi-
cient of  variation (CV). 
The intra-assay CV was 8.9% and the inter-assay CV was 
10.5%.
 
The white cell count (WCC) was analysed using fresh 
EDTA whole blood on the Siemens ADVIA 2120 (Berlin 
and Munich, Germany) haematology analyser.
 
The CD4+ count and %CD 38/8 were determined by 
means of  flow cytometry using fresh EDTA whole blood 
on the Becton Dickinson (BD) MultiTest CD3-FITC/
CD8-PE/CD45-PerCP/CD4-APC  and CD8-FITC/
CD38-PE/CD3-PerCP for CD4+ and CD38+ count re-
spectively together with TruCOUNT tubes (BD Biosci-
ences, San Jose, California) and analysed by BD FACS-
Calibur.
 
The ACL TOP (Beckman Coulter Inc., Fullerton, CA) 
instrument together with the fibrinogen-C and D-dimer 
HS 500 reagent kit by HemosIL® (Bombay, United States) 
was used to determine fibrinogen and D-dimer concen-
trations respectively.
 
The IMMAGE analyser (Beckman Coulter Inc., Fuller-
ton, CA) was used to determine hsCRP concentrations. 
 
Serum IgG and albumin levels were determined using the 
Siemens ADVIA®1800 (Berlin and Munich, Germany) 
chemistry analyser.
 
All laboratory tests were performed at enrolment and 
serum was stored at -70◦C for E-selectin determination. 




Data was analysed using STATISTICA v10.0 (Statsoft 
Inc.) and Microsoft® Excel® (Microsoft, Seattle, WA, 
USA). Descriptive statistics were used to analyse each pa-
rameter in terms of  distribution: minimum, maximum, 
median, mean, standard deviation (SD) and statistical sig-
nificance. Pearson correlation coefficient was performed 
for normally distributed data. The Spearman Rank cor-
relation was performed for non-parametric data. Analysis 
of  variance (ANOVA) was used to compare two or more 
groups of  data that was normally distributed. A p-value 
≤0.05 was considered statistically significant.
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Results
The two groups were well-matched for age with a mean 
age of  32 ±7.7 years for the HIV-infected group and 29 
±8.3 years for the control group. Furthermore, all the 
participants were recruited from the same HCT clinic 
and thus were of  the same ethnicity and from the same 
socio-economic background.
Table 1 shows the mean ± SD for the various analytes 
tested. We found that the albumin, WCC and CD4+ count 
in the HIV-infected group were significantly lower com-
pared to the control group. The % CD38/8, hsCRP and 
D-dimer levels were significantly higher in the HIV-in-
fected group compared to the control group. Fibrinogen 
and E-selectin levels however exhibited no significant dif-
ferences between the two groups. 
Table 1: Analyte levels (means ± SD) in the HIV-infected and HIV-negative participants 
 
 Analytes Reference 
Interval 
 HIV-infected 
(mean ± SD 
HIV negative 
(mean ± SD) 
 P- value 
E-selectin (ng/mL) 11.78-160.72 135.9±60.7 137.0±63 0.84 
WCC (x109cells/L) 4.0-10.0  4.92±1.67 6.08±1.96 <0.01* 
CD4+count (cells/mm3) 500-1200 394.8 ±216.4 823.9±255.8 <0.01* 
%CD38/8 0.93-7.03 30.9±19.6 13.2±11.8 <0.01* 
Albumin (g/L) 35-52 40±3.7 44±3.4 <0.01* 
IgG (g/L) 7-16 28.4±11.1 16.9±4.3 <0.01* 
Fibrinogen (g/L) 2-4 2.81±0.61 2.85±0.66 0.65 
D-dimer (mg/L) 0.0-0.25 0.32±0.21 0.22±0.09 <0.01* 
Log10 hsCRP (mg/L) - 0.56±0.58 0.29±0.56 <0.01* 
hsCRP (mg/L) 0.0-7.5 8.15±11.32 4.08±5.33 <0.01* 
Log10 E-selectin 
(ng/mL) 
- 2.09±0.2 2.1±0.18 0.84 
     *indicate statistical significance (p < 0.05) 
E-selectin levels were correlated with all the other ana-
lytes tested in both groups. There was a significant cor-
relation between E-selectin and albumin in the HIV-neg-
ative group and a near significant correlation with the 
WCC in the HIV-positive group. Furthermore, E-selectin 
did not correlate significantly with any of  the other ana-
lytes in both groups (Table 2)
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Table 2: Correlation between E-selectin and other analytes in both groups  
(Spearman r and p values) 
 
Analytes 
compared to      
E-selectin 






p-value for  
HIV -negative 
CD4+count -0.14 0.13 0.03 0.83 
%CD38/8 -0.02 0.88 -0.04 0.81 
Albumin 0.04 0.66 0.25 0.05* 
IgG -0.04 0.67 -0.15 0.22 
hsCRP 0.07 0.44 0.07 0.60 
D-dimer -0.00 0.99 0.06 0.62 
Fibrinogen 0.15 0.16 0.03 0.79 
WCC 0.18 0.07 -0.05 0.69 
      *indicate statistical significance (p < 0.05) 
After finding a near significance between E-selectin and 
the WCC in the HIV-infected group, further correla-
tions were performed with E-selectin and the differential 
count.  We found that all the parameters in the differential 
count contributed to the near significance of  the WCC. 
However, we concluded that the neutrophils contributed 
the largest portion, due to the significant positive correla-
tion (r = 0.83) observed (Table 3). 
Table 3: Correlation between E-selectin and differential count parameters 





r-value p-value r-value p-value 
Neutrophils 0.83* <0.01 0.90* <0.01 
Lymphocytes 0.44 <0.01 0.51 <0.01 
Monocytes 0.59 <0.01 0.67 <0.01 
Eosinophils 0.29 <0.01 0.09 0.47 
Basophils 0.48 <0.01 0.37 <0.01 
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Discussion
Chronic inflammation in HIV infection is an important 
cause of  disease progression and is associated with an in-
creased risk of  inflammation-associated conditions such 
as CVD and cancer.3,29 The purpose of  this study was 
to determine E-selectin levels in ART-naïve HIV-infected 
ART-naïve individuals, compare these to E-selectin levels 
in controls and correlate them with markers of  HIV dis-
ease severity, inflammation and coagulation. We hypoth-
esized that E-selectin and other markers of  CVD would 
be increased in our untreated HIV-infected group due to 
heightened levels of  inflammation. 
 
Various parameters of  inflammation and immune activa-
tion, such as D-dimer and hsCRP have been studied pre-
viously and shown to be independent risk factors for the 
development of  heart disease.38,39
 
Previous studies on  local HIV populations both treat-
ment-naïve and on treatment have found abnormal se-
rum protein electrophoresis patterns suggestive of  poly-
clonal hypergammaglobulinaemia and increased IgG.40,41. 
 
Previous studies have found that ART is unable to re-
pair the immune damage caused by HIV infection, thus 
recommendations for earlier initiation of  ART have re-
sulted.42 In resource-limited settings the roll-out of  ART 
remains a challenge43 and therefore, it becomes important 
to identify individuals who may be at increased risk of  
these conditions.
 
The underlying pathophysiology of  CVD is atheroscle-
rosis, which leads to endothelial dysfunction.44 E-selec-
tin, preferentially found on endothelial cells is a mark-
er of  endothelial dysfunction.45 Furthermore, cytokines 
released during the inflammatory process activate endo-
thelial cells, resulting in the up-regulated expression of  
E-selectin.11 
 
Previous studies examining the effects of  HIV infection 
on E-selectin levels have been controversial.31-37 Some 
studies have shown that HIV TAT-protein directly upreg-
ulatesE-selectin.31 Kristoffersen et al found no difference 
in the E-selectin level before and after ART initiation; 
however they found that ART significantly increased cho-
lesterol, triglyceride and LDL-cholesterol levels, which are 
major contributors to atherosclerotic plaque formation.33 
Rönsholt et al found that E-selectin levels were decreased 
by ART but never normalised. Furthermore, none of  the 
parameters tested, including E-selectin, correlated with 
the CD4+ count or viral load.34 Two studies by Graham 
et al found E-selectin levels to be increased during the 
acute phase of  HIV infection but not during the chron-
ic phase,35,36 suggesting that E-selectin is a positive acute 
phase reactant. This was an important finding and could 
explain the lack of  increased E-selectin in our study, as 
our cohort were all in the chronic stage of  the infection. 
 
Calza et al found that E-selectin levels were significant-
ly increased in the HIV-infected ART-naïve group com-
pared to the HIV infected group on ART; these were also 
higher than the HIV negative control group. Further-
more, they found that E-selectin levels correlated with an 
elevated viral load and decreased CD4+ count. However, 
the HIV positive treatment-naïve group were older (me-
dian age 40 years) than our study group and consisted 
of  5/50 females compared to the HIV negative control 
group with a median of  32 years consisting of  13/51 fe-
males. Our study had a predominance of  younger females 
in both groups and we showed that age and gender did 
impact on the results. The Calza study gave no indication 
that statistical analysis was corrected for age and gender.37
 
 
Our HIV-infected group, although clinically asymptom-
atic, all presented in the chronic stage of  infection which 
was evident in the decreased CD4+ count; with a mean of  
394.8±216.4 cells/mm3 compared to 832.9±255.8 cells/
mm3 in the control group (p<0.01). In our study we found 
both the ART-naïve HIV infected group (135.9±60.7ng/
mL) and the control (137.6±63.0 ng/mL) group’s E-se-
lectin to be in the upper limit of  normal reference range, 
suggesting that our cohort may have underlying chronic 
inflammation regardless of  HIV infection. A review on 
the immune system of  African children found that mal-
nutrition and micronutrient deficiency from infancy may 
cause irreversible damage to the immune system leading 
to compromised immune surveillance from early child-
hood.43 This predisposes individuals to opportunistic in-
fections which promote an altered immunity, early senes-
cence of  the immune system and a depleted naïve CD4+ 
T-cell pool. We hypothesize that since our study popula-
tion is from a low socio-economic setting where children 
often do not receive the adequate nutrition needed for 
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sustained growth and strong immunity, this may be the 
source of  underlying chronic inflammation.
 
Analysis of  markers tested for inflammation found that 
hsCRP was significantly higher (p=0.01) in the HIV-in-
fected group compared to the control group, confirming 
the presence of  increased inflammation in our HIV-in-
fected group. Albumin levels were significantly lower 
(p<0.01) in the HIV-infected group compared to the con-
trols further supporting the presence of  ongoing inflam-
mation. In addition, hsCRP showed a significant inverse 
correlation with albumin (r= -0.32, p<0.01) highlighting 
the value of  these markers in this setting. IgG was found 
to be significantly increased (p<0.01) in the HIV-infect-
ed group compared to the controls, suggesting the pres-
ence of  marked B-cell activation and possibly indicating 
the presence of  ongoing bacterial translocation due to a 
“leaky gut”.29 The % CD38/8+ T-cells was significantly 
higher (p<0.01) in the HIV-infected group compared to 
the controls, confirming significant cellular activation is 
taking place due to the viral load and ongoing immune 
stimulation.
 
Markers of  coagulation tested indicated no difference 
(p=0.65) in the fibrinogen levels of  the HIV-infected 
group. Fibrinogen is an acute phase reactant and there-
fore may not be raised in a more chronic stage of  in-
fection. Importantly, the D-dimer was significantly higher 
(p<0.01) in the HIV-infected group. The SMART study 
found that D-dimer was an independent risk factor for 
all-cause mortality30, suggesting that our study group is 
at increased risk. Since the Strategies for Management of
Antiretroviral Therapy (SMART) study, various other 
studies have examined the association between HIV in-
fection, anti-retroviral therapy ART and D-dimer with 
all-cause mortality.27,46,47 
In addition, D-dimer levels in our study showed inverse 
relations with the CD4+ count and albumin (r= -0.35 and 
r= -0.41 respectively, both p<0.01) and positive correla-
tions with the viral load, hsCRP and IgG (r=0.34, 0.27 
and 0.41 respectively, all p=<0.01), thus the D-dimer 
would be a valuable marker of  immune activation and 
possible risk for thrombosis in this setting. 
 
E-selectin levels showed significant positive correlation 
(r=0.18, p=0.02) with age, which supports the age-relat-
ed increase in E-selectin levels. This can possibly be ex-
plained by the oxidative stress theory of  age: that older in-
dividuals experience increased oxidative stress on tissues, 
such as endothelial cells causing the up-regulation of  ad-
hesion molecules such as E-selectin.48,49  E-selectin levels 
were found to be significantly higher in males (p=0.01). 
However, after correcting E-selectin for gender, no dif-
ference was found for these levels in the HIV-infected 
group compared to the controls, and males still had high-
er E-selectin levels regardless of  their HIV status. Both 
the significance of  age and gender has been demonstrat-
ed in various other studies.50-52 After the age of  forty, the 
risk of  CVD is increased by up to 49% in males and 32% 
in females, with males being 3.4 times more susceptible 
due to their naturally higher expression of  E-selectin.50 
E-selectin levels were correlated with all the markers of  
disease severity, inflammation and coagulation in our en-
tire cohort and we found no correlation with any of  the 
parameters tested. We also correlated E-selectin with all 
the parameters in the HIV-infected group and controls 
respectively and found that E-selectin correlated signifi-
cantly (p=0.05) with albumin in the control group and 
neared significance with the WCC(p=0.07) in the HIV 
infected group.
 
The WCC was significantly decreased in the HIV-infected 
group which may reflect both a decreased CD4+ count 
and decreased neutrophil count. We therefore further 
correlated the WCC with the differential count subsets 
to determine which leukocyte contributed to the correla-
tion. Interestingly, the WCC correlated most strongly to 
the neutrophil count. This may reflect the increased traf-
ficking and consumption of  neutrophils at sites of  infec-
tion or inflammation, effectively removing them from the 
circulation.
Conclusion
Our study had a few limitations. We had a small study 
population and did not have any participants who were 
on ART to compare to our study population. Also, we 
only determined E-selectin and did not determine other 
emerging cardiovascular risk markers. Although HIV-in-
fection leads to increased CVD and we have previously 
determined that our cohort indeed has such a risk, we 
found no significant difference in E-selectin levels be-
tween HIV-infected and non-infected individuals. We 
concluded that E-selectin is not a valuable marker during 
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the chronic stage of  HIV infection and recommend that 
tests such as D-dimer, hsCRP, albumin and IgG be uti-
lized to identify individuals who may be at increased risk 
of  disease progression or CVD in HIV infection.  The 
cost-effectiveness of  a combination of  these markers will 
need to be determined in resource-limited settings.
 
Future studies that take into account the time of  serocon-
version may find E-selectin to be a better marker of  early, 
acute inflammation and follow-up studies, monitoring the 
development of  CVD or atherosclerosis plaque develop-
ment in this cohort would be of  value. 
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